Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Lixte Biotechnology Holdings (LIXT) Return on Equity (2016)

Lixte Biotechnology Holdings' Return on Equity history spans 6 years, with the latest figure at 1.64% for Q3 2016.

  • For Q3 2016, Return on Equity rose 74.0% year-over-year to 1.64%; the TTM value through Sep 2016 reached 1.64%, up 74.0%, while the annual FY2015 figure was 9.65%, N/A changed from the prior year.
  • Return on Equity reached 1.64% in Q3 2016 per LIXT's latest filing, down from 1.54% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 98.24% in Q1 2012 to a low of 180.17% in Q1 2014.
  • Average Return on Equity over 5 years is 12.84%, with a median of 6.28% recorded in 2012.
  • Peak YoY movement for Return on Equity: plummeted -17173bps in 2014, then surged 17771bps in 2015.
  • A 5-year view of Return on Equity shows it stood at 7.27% in 2012, then tumbled by -312bps to 29.93% in 2013, then skyrocketed by 45bps to 16.5% in 2014, then surged by 78bps to 3.64% in 2015, then skyrocketed by 55bps to 1.64% in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Return on Equity are 1.64% (Q3 2016), 1.54% (Q2 2016), and 2.52% (Q1 2016).